Data-driven stock analysis, valuation deep dives, and financial forensics. Every article backed by the numbers.
Gold is trading near all-time highs while Newmont sits at 25x earnings with a 2.2% yield. The ceasefire doesn't eliminate the structural demand drivers pushing gold higher.
At 182x forward earnings and 34x revenue with negative operating margins, Cloudflare's $74B market cap requires a decade of flawless execution that even great companies rarely deliver.
Rio trades at 15.5x earnings with a 4.3% yield. BHP trades at 18.2x with a 1.8% yield. The valuation gap has widened — and we think the market has picked the wrong horse.
A $2.8 trillion company at a sub-15x EBITDA multiple deserves a harder look than consensus is giving it.
Precision agriculture software at 70%+ margins, a $55B finance arm stabilising earnings, $7.2B in well-timed buybacks, and a permanently reset cost structure — all hidden behind a cyclical revenue decline.
Block tripled revenue in four years while turning operating income positive for the first time. At $40 billion market cap, the market is still pricing the losses that no longer exist.
At 9.6x forward earnings and a 6.3% dividend yield, Pfizer trades cheaper than every large-cap pharma peer while the base business — excluding COVID — has grown 29% since 2021.
BAC trades at 13x forward earnings while growing net interest income at 12% annually. Management just flagged international expansion as the next growth lever — the market yawned.
At 14.4x forward earnings with a 22% net margin, 2.8% dividend yield, and zero net debt, EOG offers best-in-class cost structure at a 25% discount to ConocoPhillips.
GE Aerospace's LEAP and GE9X engine orders are running at record levels, and management is converting backlog into shareholder returns at a pace that would make any capital allocator envious.
COP is the best-run E&P in the world. But at 32x forward earnings with a consensus target below the current price, the Marathon acquisition adding leverage, and Iran supply returning, the risk-reward has flipped.
Tesla's revenue declined for the first time in a decade while the stock trades at 172x forward earnings. The delivery-production gap we flagged last month has widened further.
Revenue surged 38% to $65.2B in FY2025 as Mounjaro and Zepbound scaled. With manufacturing constraints easing and retatrutide data approaching, we're raising our revenue estimate to $90-100B by 2028.
The ceasefire removes the Hormuz tail risk, but RTX's order backlog hit a record $217 billion. Defence spending is structural, not cyclical — and the market briefly forgot that.
At 3.5x revenue with gross margins improving 28 percentage points in two years and the R2 entering production in 2026, Rivian's $19B market cap prices in permanent failure that isn't coming.